09:02:09 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaMERK Equities
SektorHälsovård
IndustriBioteknik
Nykode Therapeutics är verksamma inom bioteknik. Bolaget är idag specialiserade inom forskning och utveckling av immunologiska terapier och vacciner. Lösningarna används huvudsakligen för behandling av patienter med cancersjukdomar samt övriga allvarliga hälsotillstånd som kräver långsiktig behandling. Störst verksamhet återfinns inom den europeiska marknaden.

Kalender

2022-11-23 Kvartalsrapport 2022-Q3
2022-08-24 Kvartalsrapport 2022-Q2
2022-05-16 Kvartalsrapport 2022-Q1
2022-05-13 Ordinarie utdelning NYKD 0.00 NOK
2022-05-12 Årsstämma 2022
2022-03-31 Bokslutskommuniké 2021
2021-12-22 Extra Bolagsstämma 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-12 Kvartalsrapport 2021-Q1
2021-05-06 Ordinarie utdelning NYKD 0.00 NOK
2021-05-05 Årsstämma 2021
2021-04-21 Bokslutskommuniké 2020
2020-11-17 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-07-07 Split NYKD 1:5
2020-07-06 Extra Bolagsstämma
2020-05-12 Kvartalsrapport 2020-Q1
2020-04-22 Extra Bolagsstämma
2021-12-03 17:26:28
Oslo, Norway, December 3, 2021 - The following primary insiders/primary
insider's related parties have today bought a total of 282,000 shares in Nykode
Therapeutics (formerly Vaccibody*) at NOK 74.60 per share:

Datum AS 94,000
RASMUSSENGRUPPEN AS 94,000
Caaby AS 9,400
Victoria India Fund AS (Andenaesgruppen) 84,600
Total 282,000

Following the above transactions Jan Haudemann Andersen (board member) and the
Datum Group holds 40,357,050 shares (including 11,728,250 shares through Datum
AS), Rasmussen Group of companies holds 34,030,750 shares (of which
RASMUSSENGRUPPEN AS, in which Trygve Lauvdal (member of the Nykode Therapeutics
board) is an employee, owns 28,180,750), Christian Åbyholm (board member)
through Caaby AS holds 2,005,295 shares and 100,000 warrants and Andenaesgruppen
(through Victoria India Fund AS) represented by Christian Åbyholm owns
17,255,175 shares and in addition Norda ASA represented by Christian Åbyholm
owns 7,996,755 shares.

In order to cover tax liabilities, primary insider Agnete B. Fredriksen, Chief
Innovation & Strategy Officer, has today sold 282,000 shares in Nykode
Therapeutics through Viginti AS at NOK 74.60 per share. Following the sale,
Agnete B. Fredriksen holds 48,000 shares through Viginti AS and 3,834,900
warrants.

Please see further details in the attached document.

* Vaccibody AS is changing its name to Nykode Therapeutics AS. The change of
name was approved by an EGM held on November 30, 2021.